Drug Trial Radar · NCT05363397
Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke
Last checked: Nov 19, 2026Latest source record: Dec 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Sep 27, 2023
Primary completion
Feb 1, 2026
Study completion May 1, 2026
Sponsor
- Lead sponsor
- The Florey Institute of Neuroscience and Mental HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Neuroscience Trials Australia
- First posted
- May 5, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
STARS is a prospective, multicentre, open-label, dose escalation, Phase IIa study to assess the safety and tolerability of TBO-309, an adjuvant antiplatelet therapy, in patients with AIS. Acute ischaemic stroke (AIS) is caused by a severe blockage of an artery leading to immediate reduced blood flow to part of the brain. Standard therapies target the blocked artery by either dissolving the blockage or removing the blockage. However, even after successful treatment, re-blockage of arteries can occur. The use of an antiplatelet therapy, TBO-309, in addition to standard therapies offers the possibility of improved restoration of blood flow and reduced rates of artery re-blockage.
Conditions
- Acute Ischemic Stroke
Interventions
TBO-309Drug
TBO-309 is a potent, selective and ATP competitive PI3Kβ inhibitor which blocks platelet activation adhesion/aggregation and promotes platelet disaggregation, thereby specifically inhibiting thrombosis without interfering with normal haemostasis.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients with ICH within 24-36 hours of study drug (TBO-309) commencement.Time frame: Within 24-36 hours of initiation of study drug
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia · Recruiting
Liverpool Hospital
Liverpool, New South Wales, Australia · Recruiting
John Hunter Hospital
New Lambton Heights, New South Wales, Australia · Recruiting
Prince of Wales Hospital
Randwick, New South Wales, Australia · Recruiting
Royal Adelaide Hospital
Adelaide, South Australia, Australia · Recruiting
Eastern Health- Box Hill Hospital
Box Hill, Victoria, Australia · Recruiting
Royal Melbourne Hospital
Parkville, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.